Project description DEENESFRITPL Engineered NK cells against cancer Tumours have evolved mechanisms for evading immune system responses including T cell exhaustion. To address this problem, scientists have come up with immunotherapy strategies to awaken or reeducate the immune system against cancer. Chimeric antigen receptor (CAR) natural killer (NK) cells are genetically engineered to recognise a specific target antigen. Despite their great promise, CAR-NK cell production is laborious and costly. The ERC-funded CHEMCELL project aims to address this limitation through an innovative labelling and engineering approach. Researchers will produce antibody-modified NK cells and test them against conventional CAR-NK cells for their anti-cancer efficiency. Show the project objective Hide the project objective Objective Our immune system evolved to protect our bodies from different invaders and to fight against infections and diseases. Immune cells use sophisticated ways to detect and destroy abnormal cells, while sparing our own cells. Unluckily, cancer cells often develop sneaky tricks enabling them to evade this protecting machinery and to survive and proliferate. Immunotherapy, an emerging concept of treatment, aims to employ the power of immune system to fight cancer by boosting or reeducation of immune cells. One of the approaches, the adoptive cell transfer therapy, especially in the form of chimeric antigen receptor (CAR) cells, has shown an unprecedented success in the treatment of certain types of cancer. CAR cells are genetically modified immune cells engineered to recognize and kill cells with specific cancer antigen. Unfortunately, production of genetically modified CARs is problematic, inefficient, time consuming and therefore, associated with high costs. New approaches enabling production of modified immune cells more effectively, faster and cheaper could therefore change the way the therapy is used. Within this proposal, we will explore the potential of an innovative approach for production of chemically engineered immune cells and their application in immunotherapy. In particular, we will employ our technology based on combination of metabolic engineering and subsequent biocompatible chemical labeling to produce an antibody modified natural killer (NK) cells that we will investigate in cancer killing experiments. We will perform a side-by-side comparison of our technology with the ‘traditional’ CAR-NK cells both, in vitro and in vivo, to evaluate the pros and cons of both approaches. Finally, in collaboration with our Tech Transfer Office, we will present the technology to potential stakeholders to bring it to the next step in the form of patent licensing or eventually, develop the technology further within spin-out company. Fields of science engineering and technologyindustrial biotechnologymetabolic engineeringmedical and health sciencesclinical medicineoncologyengineering and technologychemical engineeringmedical and health sciencesbasic medicineimmunologyimmunotherapy Programme(s) HORIZON.1.1 - European Research Council (ERC) Main Programme Topic(s) ERC-2022-POC2 - ERC PROOF OF CONCEPT GRANTS2 Call for proposal ERC-2022-POC2 See other projects for this call Funding Scheme HORIZON-AG-LS - HORIZON Lump Sum Grant Coordinator USTAV ORGANICKE CHEMIE A BIOCHEMIE, AV CR, V.V.I. Net EU contribution € 150 000,00 Address Flemingovo nam. 542/2 16610 Praha 6 Czechia See on map Region Česko Praha Hlavní město Praha Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00
